Lightlake Therapeutics, which is developing intranasal naloxone to treat eating disorders, has announced the appointment of board member Kevin Pollack as Chief Financial Officer. Pollack joined the board of directors in April 2012.
Lightlake Chief Executive Roger Crystal said, “It has been a privilege to work with Kevin since he joined our Board and when we look to our future as a company, we believe now is the appropriate time to appoint him as our CFO. Kevin has demonstrated to us his expertise in both finance and strategy while serving on our Board, and by appointing him as our CFO we believe he will be in a better position to utilize his talents as we strive to build a platform of biopharmaceutical solutions to common addictions and related disorders.”
The company also said that it expects to launch development programs for the treatment of addictions to opioid painkillers, methadone, cocaine, and amphetamine after receiving several patents recently.
Read the Lightlake press release.
